The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Are you a print subscriber? Activate your account. By Ad Age Studio 30 - 1 day 13 hours ago By Ad Age Staff - 1 day 15 hours ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Are you a print subscriber? Activate your account. By Ad Age Studio 30 - 1 day 13 hours ago By Ad Age Staff - 1 day 15 hours ago By Ad Age and Creativity Staff - 1 day 17 hours ago 1 day 19 hours ago ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health, GSK, said: “At ViiV Healthcare we believe that everyone, no matter where they live, should have the freedom to be their authentic ...

Champix and another oral smoking cessation therapy, GSK's Zyban (bupropion), saw restrictions placed on their use after they ...